Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, NuGen Technologies

CombiMatrix Molecular Diagnostics has completed the clinical validation of HemeScan MDS, an array comparative genomic hybridization-based test for myelodysplastic syndromes, according to its parent company CombiMatrix.
HemeScan MDS is designed to detect clonal prognostic markers in bone marrow aspirates from patients with refractory anemia. The test combines diagnosis of pre-leukemia with individualized risk stratification and treatment planning.
The HemeScan MDS test is available to the clinical community through both routine clinical sample processing at CMDX as well as through the company’s Technical Only Program for reference laboratories that allows clinicians to do their own analysis, CombiMatrix said.

NuGen Technologies said this week that its Ovation Systems for amplification of RNA from small and degraded samples have been validated for use with both the Agilent and Illumina microarray platforms.
Ovation was previously validated for use with the Affymetrix GeneChip platform and for direct qPCR analysis.
NuGen said that its Ovation amplification kits now enable detection of low-abundance transcripts present in limited and degraded RNA for gene expression analysis. According to the firm, its FL-Ovation cDNA Fluorescent Module has been designed for use with Agilent DNA gene expression arrays. For Illumina whole-genome expression arrays, the amplified cDNA can be labeled following a brief platform-specific labeling protocol, the company said.